Showing results (221-230 of 346) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Cancer Research Campaign phase II trial of temozolomide in metastatic melanomaN M Bleehen, E S Newlands, S M Lee, et al.
Cancer Research|August 1, 1994
Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytesS M Lee, P J O'Connor, N Thatcher, et al.
British Journal of Cancer|February 14, 1998
Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitroA T McGown, G Jayson, G R Pettit, et al.
Cancer Immunology, Immunotherapy : CII|October 1, 1994
Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitroC Scheid, J Prendiville, G Jayson, et al.
Biochemical Pharmacology|June 1, 1989
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivoM J Lind, A T McGown, J A Hadfield, et al.
British Journal of Cancer|January 1, 1989
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity studyW P Steward, J H Scarffe, R Austin, et al.
Cancer Research|October 10, 1998
Phase I trial of temozolomide using an extended continuous oral scheduleC S Brock, E S Newlands, S R Wedge, et al.
British Journal of Cancer|April 1, 1992
Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials CommitteeS B Kaye, M Brampton, P Harper, et al.
British Journal of Diseases of the Chest|January 1, 1984
Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancerN Thatcher, D Honeybourne, J Wagstaff, et al.
British Journal of Cancer|January 1, 1997
Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapyS M Lee, J A Radford, W D Ryder, et al.
Pageof 35